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Abstract
Coronary artery disease (CAD) remains one of the leading causes of mortality and disability in Ukraine. Arterial hypertension 
(AH) is one of the most common diseases and a leading risk factor for coronary artery disease.
The aim of the work is to evaluate the antianginal activity of meldonium in the complex therapy in patients with CAD with 
stable angina and concomitant AH.
Materials and methods. The study included 82 patients with CAD, stable angina pectoris II–III functional class, including 
52 patients with concomitant AH stage II. The patients were divided into 2 groups. Patients in group 1 were prescribed meldonium at a 
dose of 750 mg/d for 2 months in addition to basic therapy for the underlying disease. Patients in group 2 continued basic antianginal, 
disaggregant, hypolipidemic therapy.
Results. The use of meldonium led to a decrease in the frequency of angina attacks and the need for nitroglycerin. From the 1st 
month of therapy and up to 2 months treatment decreased it consumption by 63 and 82.3 % respectively. Adding meldonium to basic 
therapy led to a likely reduction in shortness of breath, episodes of palpitations, tinnitus, and headache. In all patients, after the treat-
ment, an increase in exercise tolerance was observed, which was more pronounced in the group where patients were receiving meldoni-
um. In the group of patients receiving meldonium, normalisation of blood pressure was faster and more pronounced.
Conclusions. Meldonium has antianginal activity, which is manifested by an increase in the physical tolerance of patients, a 
decrease in the frequency of angina attacks, the need for sublingual nitroglycerin intake and improvement in the well-being of patients. 
Additional use of meldonium promotes faster and better normalization of blood pressure. The use of meldonium in the complex therapy 
of patients with stable angina and concomitant AH allows to increase the effectiveness of traditional antianginal therapy and to improve 
the quality of life of such patients.
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1. Introduction
Coronary artery disease (CAD) remains one of the leading causes of mortality and disability 
in Ukraine and abroad [1, 2]. Moreover, the prevalence of stable angina and heart failure in East-
ern Europe patients in comparing with other developed countries was observed (4.0 and 7.8 times 
respectively) [3]. Arterial hypertension (AH) is one of the most common diseases and a leading 
risk factor for coronary artery disease, including myocardial infarction, stroke, vascular lesions, 
chronic kidney disease, and premature death [4, 5].
The treatment of coronary artery disease often remains a difficult task, due to the limited 
capabilities of antianginal drugs and the presence of a number of contraindications for cardiac 
surgery. This is especially true for patients with concomitant hypertension, which significantly 
worsens the patient’s condition and increases the risk of complications. One of the promising direc-
tions for improving the therapy of coronary heart disease is the use of myocardial cytoprotectors in-
cluded in the complex therapy. The pharmacokinetics of modern cytoprotectors are based on their 
ability to increase myocardial resistance to ischemia, to maintain the viability of ischemic tissues 
and to restore their functional activity [6]. In addition, they have pleiotropic effects. One of them is 
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the stimulation of endothelial nitric oxide (NO) synthesis, which provides natural vasodilation and 
helps to reduce blood pressure [7, 8].
The key pathogenic link in the development of coronary artery disease is ischemia, as well 
as the activation of free radical processes in ischemic tissue, which destroy cellular structures. 
When concomitant hypertension is present, tissue deterioration is due to endothelial dysfunction on 
the background of increased blood pressure (BP). That is why the use of cytoprotectors, which have 
antioxidant properties and can also positively affect NO excretion, is appropriate [9, 10].
The aim of the work was to evaluate the antianginal activity of meldonium in the complex 
therapy of patients with coronary artery disease with stable angina and concomitant arterial hy-
pertension.
2. Materials and methods 
The study included 82 patients with coronary artery disease, stable angina II (43 people) – 
III (39 people) functional classes (53.3±7.5 years, men – 71, women – 11), of whom – 52 patients 
with concomitant hypertension (hypertension) stage II. All of them were examined and observed 
on the basis of the myocardial infarction department No. 2 of the Ivano-Frankivsk regional clinical 
cardiology centre from 2017 to 2019.
Inclusion criteria: age 40–60 years; the presence of coronary artery disease, stable angi-
na pectoris II–III functional class, confirmed clinically (typical chest pain syndrome) and with 
paired veloergometry (VEM) - depression of the segment ST>1 mm; previous intake of cardiose-
lective β-blockers (bisoprolol or metoprolol) and/or prolonged nitrates (isosorbide-5-mononitrate), 
acetylsalicylic acid, atorvastatin or rosuvastatin in individual dose regimens before inclusion into 
research for 4 months at least; the presence of informed consent. 
Exclusion criteria: individual drug intolerance; hemodynamically significant disorders of 
rhythm and conduction; history of acute coronary syndrome earlier than 6 months before the start 
of the research; AH III stage; chronic circulatory insufficiency greater than stage IIA and greater 
than II FC; obesity of any genesis more than II degree; diabetes mellitus or impaired glucose toler-
ance; chronic renal, hepatic and respiratory failure.
The members of the Ethics Commission (extract from protocol No. 8 dated January 23, 2017) 
at the Ivano-Frankivsk National Medical University decided that this study would not contradict 
the main provisions of the GCP, Convention Council of Europe on human rights and biomedicine, 
the Helsinki Declaration of the World Medical Association on ethical principles for the conduct of 
scientific medical research with the participation of man and the Law of Ukraine “On Medicines”. 
All patients signed an informed consent to participate in a clinical trial. 
Patients were divided into 2 groups of 42 and 40 patients, respectively. For patients in group 
1 meldonium were prescribed at a dose of 750 mg/d for 2 months in addition to basic therapy for 
the underlying disease. Patients in group 2 continued the basic antianginal, disaggregant, hypolip-
idemic therapy. For each patient from group 2 first a dose of β-blocker was selected, and only in the 
case of its inefficiency, prolonged nitrates (isosorbide-5-mononitrate) were administered. Patients’ 
tolerance to physical activity was assessed by step intermittent paired VEM tests (duration of each 
stage and pause was 4 min) with the calculation of threshold power (Wthreshold), as well as the total 
power Wtotal=(W1+W2+...) * 4+Wls*Tls/60, where W1, W2 is the power of fully completed stages, Tls 
is the duration of the last stage (min), the double execution index (DEI=Wthreshold, SBP/100, where 
SBP is a systolic blood pressure at the height of the threshold load). The total load duration (Ttotal) 
was recorded. Additionally, a 6-minute walk test was performed. The need for sublingual nitro-
glycerin and the frequency of angina attacks per day were evaluated. The dynamics of indicators 
of systolic and diastolic blood pressure (SBP and DBP, respectively) were evaluated. The dynamics 
of additional clinical features of patients such as shortness of breath, palpitations, rapid fatigue, 
heart failure, tinnitus, headache and dizziness were evaluated. All investigated parameters were 
evaluated monthly throughout the observation period. 
Statistical treatment of the obtained results was carried out with the program “Statistica 6.0” 
(Free Trial Version https://www.tibco.com/), using the Newman-Keuls criterion, the data were con-
sidered reliable when the difference between the mean values р˂0.05.
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The use of meldonium led to a decrease in the frequency of angina attacks and the need for 
nitroglycerin. From the 1st and up to 2 months of treatment, it decreased by 63 and 82.3 % respec-
tively (Table 1). There was no significant change in these parameters during basic therapy.
Table 1
Effect of meldonium therapy on the frequency of angina attacks and the daily need for nitroglycerin in doses 
(1 dose = 0.5 mg) in patients with coronary heart disease
Indicator Group Before treatment
Treatment period
1 month 2 month
Attacks per day
meldonium 3.11±0.24 1.15±0.33* 0.55±0.16*
basic therapy 2.11±0.34 1.76±0.33 1.83±0.34
Nitroglycerin per day, 
number of doses  
meldonium 2.15±0.42 1.3±0.48* 0.69±0.25*
basic therapy 2.25±0.22 1.92±0.33 1.85±0.25
Note: * p<0.05 – significance of differences with the original data
When assessing the physical tolerance of patients taking meldonium, it was found that the 
value of Wthreshold after 1 month treatment increased by 24.7 %, after 2 month – by 26.1 %. Wtotal 
value also increased after 1 month by 50 %, after 2 months – by 58.6 %. At the same time, Ttotal and 
DEI increased (Table 2).
Table 2
Dynamics of VEM test indices in patients with coronary artery disease with meldonium treatment 
Indicator Group Before treatment
Treatment period
1 month 2 month
Wthreshold, W
meldonium 67.54±3.74 84.23±4.32* 85.14±4.35*
basic therapy 74.77±4.23 72.14±4.55 78.33±4.94
Wtotal, W
meldonium 461.6±24.6 692.4±31.1* 732.2±25.1*
basic therapy 445.6±23.6 451.4±26.1 435.1±25.1
Ttotal, min
meldonium 6.6±3.3 9.3±3.5* 9.3±3.9*
basic therapy 7.3±3.2 7.6±3.3 7.1± 2.6
DEI, CU
meldonium 182.5±6.2 198.5±5.2* 205.3±6.1*
basic therapy 175.3±6.5 174.6±5.4* 182.3±5.1
Note: * p<0.05 – significance of differences with the original data
In all patients with coronary artery disease, which were included in the study, a positive 
trend in reducing the frequency of detection of subjective clinical signs of the disease was observed.
Adding meldonium to basic therapy led to a likely reduction in shortness of breath, episodes 
of palpitations, tinnitus, and headache. However, it should be noted that in patients with coronary 
heart disease there was no significant reduction in rapid fatigue and dizziness (Table 3).
In all patients, after treatment, an increase in exercise tolerance was observed, which was 
more pronounced in the group where patients were receiving meldonium, as evidenced by the re-
sults of a 6-minute walk (Table 4).
All patients showed a decrease in SBP and DBP levels after treatment. In the group of 









Dynamics of clinical signs in patients with coronary heart disease with meldonium treatment (absolute data 
provided)
Indicator Group Before treatment
Treatment period
1 month 2 month
Dyspnea 
meldonium 28 (66.7 %) 25 (59.5 %)* 22 (52.4 %)*
basic therapy 29 (72.5 %) 28 (70 %) 26 (65 %)
Palpitation
meldonium 24 (57.1 %) 21 (50 %)* 19 (45.2 %)*
basic therapy 18 (45 %) 18 (45 %)* 16 (40 %)*
Rapid fatigue
meldonium 36 (85.7 %) 27 (64.3 %) 25 (59.5 %)
basic therapy 34 (85 %) 30 (75 %) 30 (75 %)
Interruptions in the 
heart activity
meldonium 16 (38.1 %) 15 (35.7 %)* 15 (35.7 %)*
basic therapy 17 (42.5 %) 16 (40 %) 15 (37.5 %)
Tinnitus
meldonium 23 (54.8 %) 22 (52.4 %)* 19 (45.2 %)*
basic therapy 12 (30 %) 11 (27.5 %)* 9 (22.5 %)*
Headache
meldonium 29 (69 %) 24 (57.1 %)* 20 (47.6 %)*
basic therapy 32 (80 %) 30 (75 %) 29 (72.5 %)
Dizziness
meldonium 21 (50 %) 18 (42.9 %) 14 (33.3 %)
basic therapy 24 (60 %) 22 (55 %) 21 (52.5 %)
Note: * – p<0.05 – significance of differences with the original data
Table 4
Results of a 6-minute walk test in patients with coronary artery disease on the background of receiving 
meldonium
Indicator Group Before treatment After treatment
6 minute walk distance, m
meldonium 362.8±23.7 507.3±22.1*
basic therapy 353±20.8 482±24.5*
Note: * – p<0.05 – significance of differences with the original data
Table 5
Dynamics of blood pressure in patients with coronary heart disease with concomitant hypertension on the 
background of treatment with meldonium
Indicator Group Before treatment After treatment
SBP mmHg
meldonium 152.4±8.9 129.6±3.56*
basic therapy 155.6±9.6 138±4.87*
DBP mmHg
meldonium 93.8±6.37 79.63±6.12*
basic therapy 94.5±5.3 81.36±4.08*
Note: * – p<0.05 – significance of differences with the original data
4. Discussion
The study allowed us to confirm data on the presence of antianginal activity in meldonium. 
It is known that the major source of energy for cardiomyocytes is free fatty acids (FFA) and car-
bohydrates, in particular glucose. During the experiments, it was proved that for synthesis of the 
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same number of adenosine triphosphate (ATP) molecules using glucose rather than free fatty acids, 
16–30 % less oxygen molecules are needed [11, 12]. Only glucose can participate in redox reactions 
in cells in the complete absence of O2. In the development of ischemia for myocardial tissues, the 
most energy-efficient ways of synthesis of ATP molecules are glycolysis and glycogenolysis. How-
ever, the utilization of that small amount of oxygen, which still enters the ischemic zone, is ensured 
mainly by the oxidation of free fatty acids by carnitine [13]. During this reaction, there is an accu-
mulation of waste products of β-oxidation of fatty acids (acylcoenzyme A and acylcarnitine) in the 
myocardium. These metabolic products contribute to the damage of cell membranes, increase the 
saturation of cardiomyocytes with calcium ions, reduce the potential action and, in sum, lead to an 
increase in the ischemic zone [14, 15]. 
The action of meldonium is based on intracellular inactivation of carnitine synthesis, 
which ensures the transport of FFA in the cell mitochondria. As a result, the f low of free FFA 
into the mitochondria decreases (a lot of oxygen is required for their oxidation), which in 
turn indirectly inhibits β-oxidation of FFA in the mitochondria, providing cytoprotection. In 
addition, meldonium by increasing the level of γ-buterobetaine stimulates the activity of NO 
synthase [16, 17]. Therefore the use of the drug can reduce the severity of vascular endothelial 
dysfunction, which is inherent in coronary artery disease and hypertension [18]. The use of 
cardiocytoprotectors additionally prevents the occurrence of undesirable side effects after re-
ceiving high doses of antianginal drugs, in particular bradycardia and hypotension. Numerous 
clinical studies have demonstrated the anti-ischemic efficacy of meldonium in patients with 
coronary heart disease, which has contributed to improving the well-being and quality of life 
of patients as a whole [19, 20].
In this regard, it is advisable to use meldonium in patients with chronic coronary pathology 
and hypertension to increase the effectiveness of antianginal and antihypertensive therapy and 
increase the resistance of the body’s antioxidant systems.
Study limitations. A limitation of the study is the fact that the data on changes in clinical 
signs in patients with coronary heart disease were based on their statements due to the lack of 
measured values and some subjectivity in this measurement, which could potentially be a source of 
inaccuracies. The lack of objective information cannot be completely avoided in real clinical prac-
tice. However, it was shown that information about dynamics of clinical signs in patients provided 
personally by themselves are suitable for use in clinical trials.
Prospects for further research. Insofar as all aspects of the effects of metabolic therapy 
and meldonium in particular on the course of coronary artery disease with concomitant hyperten-
sion are not known yet, this area of research needs further investigation.
5. Conclusions
The study showed that meldonium has an antianginal activity, which was manifested by an 
increase in the physical tolerance of patients receiving the drug, as well as a decrease in the fre-
quency of angina attacks, the need for sublingual nitroglycerin intake and improving the well-be-
ing of patients.
Additional use of meldonium promotes faster and better normalization of blood pressure.
The use of meldonium in the complex therapy of patients with stable angina and concomi-
tant arterial hypertension allows to increase the effectiveness of traditional antianginal therapy and 
to improve the quality of life of such patients.
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